ACT Advisors’s Quest Diagnostics DGX Stock Holding History

ACT Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$436K	Buy	+2,055	New	+$403K	0.14%	45

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

ACT Advisors's DGX Position: Q2 2026 in Review

ACT Advisors opened a new position in Quest Diagnostics (DGX) in Q2 2026: 2,055 shares worth $436K. The stake represents 0.14% of the portfolio and ranks #45 among its holdings.

1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

ACT Advisors held 2,055 shares of Quest Diagnostics worth $436K as of Q2 2026.
Quest Diagnostics was a new ACT Advisors position in Q2 2026.
Quest Diagnostics made up 0.14% of ACT Advisors's portfolio in Q2 2026, its #45 holding.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on ACT Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.